Alkermes plc (ALKS)
NASDAQ: ALKS · IEX Real-Time Price · USD
-0.59 (-2.36%)
At close: Jun 18, 2024, 4:00 PM
+0.08 (0.33%)
After-hours: Jun 18, 2024, 4:47 PM EDT

Alkermes Revenue

Alkermes had revenue of $1.73B in the twelve months ending March 31, 2024, with 54.01% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $350.37M with 21.83% year-over-year growth. In the year 2023, Alkermes had annual revenue of $1.66B with 49.61% growth.

Revenue (ttm)
Revenue Growth
P/S Ratio
Revenue / Employee
Market Cap
4.13B USD

Revenue Chart


Fiscal Year End Revenue Change Growth
Dec 31, 20231.66B551.61M49.61%
Dec 31, 20221.11B-61.96M-5.28%
Dec 31, 20211.17B135.00M13.00%
Dec 31, 20201.04B-132.19M-11.29%
Dec 31, 20191.17B76.67M7.01%
Dec 31, 20181.09B190.90M21.13%
Dec 31, 2017903.37M157.68M21.15%
Dec 31, 2016745.69M117.36M18.68%
Dec 31, 2015628.34M9.55M1.54%
Dec 31, 2014618.79M43.24M7.51%
Mar 31, 2013575.55M185.57M47.59%
Mar 31, 2012389.98M203.34M108.95%
Mar 31, 2011186.64M8.36M4.69%
Mar 31, 2010178.28M-148.56M-45.45%
Mar 31, 2009326.84M86.12M35.78%
Mar 31, 2008240.72M752.00K0.31%
Mar 31, 2007239.97M73.36M44.04%
Mar 31, 2006166.60M90.48M118.85%
Mar 31, 200576.13M37.07M94.92%
Mar 31, 200439.05M-8.21M-17.37%
Mar 31, 200347.27M-6.84M-12.63%
Mar 31, 200254.10M-1.93M-3.44%
Mar 31, 200156.03M33.11M144.45%
Mar 31, 200022.92M-10.97M-32.37%
Mar 31, 199933.89M8.31M32.47%
Mar 31, 199825.59M5.76M29.04%
Mar 31, 199719.83M3.91M24.55%
Mar 31, 199615.92M2.02M14.49%
Mar 31, 199513.90M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Select Medical Holdings 6.79B
Oscar Health 6.54B
PACS Group 3.34B
RadNet 1.66B
Integer Holdings 1.63B
Haemonetics 1.31B
Alvotech 114.39M
Avidity Biosciences 10.87M
Revenue Rankings